News

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander Schneider, CEO of CureLab Oncology, shares both.

Toutes ont reçu une chimiothérapie standard à base de gemcitabine, et la moitié d’entre elles ont également reçu de l’élénagène, développé par CureLab Oncology, sous forme d’une injection hebdomadaire dans le muscle.

Gabriel Levin, gynaecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc. will present new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance

Alexander Shneider, CEO of CureLab Oncology and the inventor of Elenagen, emphasizes the evolutionary significance of this therapy.

Clinical Relevance: Adding elenagen to gemcitabine significantly prolonged survival without added toxicity in platinum-resistant ovarian cancer, supporting further investigation of elenagen-based immunomodulation in combination with chemotherapy.

In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection. … How Elenagen works against cancer Elenagen’s ability to reduce chronic inflammation alters the intratumoral microenvironment, facilitating the penetration of immune cells (Tumor-Infiltrating Lymphocytes, or TILs).

Posted in Podcasts | Tagged CureLab Oncology, DNA, endogene.bio, Endometriosis, Genetics, Junevity, MHRA, Ocular diseases, Oncology, Regulatory, UK government, University of California San Francisco, Women’s health The latest episode of the DDW Highlights Podcast is now available to listen to below

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1 — currently being developed by the firm CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

Elenagen emerged from ‘serendipitous discoveries’ Elenagen, developed by biotech company CureLab Oncology, works by reducing chronic inflammation and altering the intratumoral environment, facilitating the penetration of immune cells (tumour-infiltrating lymphocytes, or TILs).